Standout Papers

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced ... 2017 2026 2020 2023 332
  1. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial (2017)
    Beatrice Seddon, Sandra J. Strauss et al. The Lancet Oncology

Immediate Impact

5 from Science/Nature 53 standout
Sub-graph 1 of 22

Citing Papers

Open-ST: High-resolution spatial transcriptomics in 3D
2024 Standout
Glioblastoma Therapy: Past, Present and Future
2024 Standout
1 intermediate paper

Works of Stephen Nash being referenced

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
2017
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
2016

Author Peers

Author Last Decade Papers Cites
Stephen Nash 252 193 447 451 63 1.6k
Misoo C. Ellison 211 437 305 462 52 2.0k
L Carpenter 77 271 310 283 40 1.7k
Robert D. Harris 114 122 176 315 107 1.7k
Lauren E. Wilson 364 330 321 138 78 1.8k
K D MacRae 182 231 250 187 65 1.9k
Martin Berry 111 314 453 617 40 1.8k
Prem Chopra 220 303 162 357 150 1.9k
Nandagudi Srinivasa Murthy 174 728 440 169 80 2.1k
Ellen Funkhouser 132 197 455 274 62 1.7k
Samuel Ariad 121 160 768 176 110 1.5k

All Works

Loading papers...

Rankless by CCL
2026